Background
Align Technology holds patents covering its Invisalign system — a method of orthodontic tooth alignment using a series of custom-made clear plastic aligners. Instead of traditional braces requiring periodic dentist adjustments, Invisalign patients receive multiple progressively shaped appliances at once and swap them on a schedule to incrementally move their teeth toward the desired final position.
Ormco Corporation, a competing orthodontic device maker, sued to have Align’s patents invalidated. Align counterclaimed, alleging that Ormco’s “Red, White & Blue” competing product infringed its patents. The district court found infringement and upheld validity. Ormco appealed, arguing that Align’s key patents were anticipated or obvious in light of prior art — specifically, unpublished clinical techniques demonstrated by orthodontist Dr. Truax at a professional seminar years before Align’s filing date.
The Court’s Holding
The Federal Circuit reversed, holding several claims of Align’s ‘611 and ‘548 patents invalid as obvious. The court found that Dr. Truax’s earlier practice — using multiple plastic appliances of incrementally different thicknesses applied sequentially to move teeth — constituted accessible prior art, even though it was never formally published. Information distributed at professional seminars to practitioners in the field qualifies as public prior art, whether or not it appears in a peer-reviewed journal.
The court found the differences between Truax’s approach and Align’s claims to be obvious design choices rather than inventive steps. Providing all treatment appliances in a single package rather than dispensing them one at a time was a routine commercial packaging decision. FDA regulations requiring manufacturers of medical devices to include instructions for use supplied motivation to add instruction sheets — another claimed feature. And where the claimed replacement interval (every 2–20 days per appliance) substantially overlapped Truax’s disclosed 14–21 day interval, the court applied the presumption that overlapping ranges are prima facie obvious.
On secondary considerations — evidence of commercial success, long-felt need, and failure of others — the court held that such evidence does not rebut obviousness unless there is a genuine nexus between the commercial success and the specific claimed features. Invisalign’s commercial success was driven in large part by its aesthetic appeal (clear aligners instead of metal braces) and the novelty of computer-aided design, neither of which was claimed in the patents at issue. Success attributable to unclaimed or already-known features does not establish that the claimed features are nonobvious.
Key Takeaways
- Prior art accessible to practitioners in a field — including techniques demonstrated at professional seminars — qualifies as public prior art, not just formally published literature.
- Routine packaging choices and standard commercial decisions do not transform an otherwise obvious invention into a nonobvious one.
- Regulatory requirements (such as FDA labeling mandates) can supply motivation to combine prior art elements without an explicit suggestion in the prior art itself.
- Overlapping numerical ranges between a patent claim and prior art create a presumption of obviousness that the applicant must overcome with evidence of unexpected results or teaching away.
- Commercial success supports nonobviousness only if it is specifically tied to the claimed features — success driven by unclaimed aesthetic, marketing, or convenience factors is irrelevant.
Why It Matters
Ormco v. Align Technology is an important pre-KSR decision illustrating the flexibility of the obviousness analysis even before the Supreme Court’s 2007 ruling in KSR International Co. v. Teleflex, which further relaxed the obviousness standard. The case shows that courts can find obviousness even without an explicit suggestion in the prior art to combine references, and that professional practice distributed at medical or dental conferences can count as public knowledge.
The decision’s treatment of secondary considerations is particularly instructive: it sets a high bar for commercial success evidence, requiring a rigorous nexus to the specific claimed features. Inventors and practitioners relying on commercial success to rebut obviousness must be prepared to demonstrate that their product’s market dominance is attributable to what the patent claims, not to other aspects of the product or business.